Featured Technology

Combination Therapy for Leukemia and Solid Tumors

Treatment for various kinase-driven cancers have advanced, but there is often a relapse after treatment is discontinued. We have identified a therapeutic cocktail that eliminates this relapse by inhibiting three complementary pathways: c-Fos, Dusp-1 and BCR-ABL tyrosine kinase.

In vivo experiments in an animal model mimicking human CML, AML, and lung cancers showed that treatment with our cocktail fully suppressed the expression of cancer stem cells. A one month drug treatment cured the mice of leukemia and eradicated the cancer stem cells while those treated with only one or two components of the cocktail relapsed, demonstrating that this cocktail provides an effective therapy for leukemia.

For more detailed information regarding this technology, please click here for a non-confidential slide deck.

  • Acute Myelogenous Leukemia (AML)
  • Chronic Myelogenous Leukemia (CML)
  • Lung Adenocarcinoma
  • Lung Squamous Carcinoma
  • Myeloproliferative neoplasms
  • and possibly other kinase-driven cancers
  • Highly effective in eliminating leukemic cells from peripheral blood.
  • Provides a curative method of treating CML, which would not require lifelong treatment, and a curative method of treating kinase resistant AML.
  • Potential platform for treating multiple cancers.
  • Cost of TKI treatment is very expensive despite being ineffective for many patients, with costs often exceeding $100,000 per year.
    • For example, 15-30% of CML patients diagnosed in the chronic phase will meet some definition of resistance to imatinib
  • According to the American Cancer Society, many studies are being done to find more effective and safer treatments for AML, CML, and non-small cell lung cancer.
“Therapy for Leukemia”
• U.S. Continuation-in-Part Patent Application No. 14/048,806
• E.P.O. Patent Application No. 12774776.4
• Canadian Patent Application No. 2,832,860

“Therapy for Solid Tumors”
• PCT Application No. PCT/US2015/033269

“Therapeutic Targeting of Myeloproliferative Neoplasms by Dusp1 Inhibition”
• U.S. Provisional Patent Application No. 62/170,834

“Small Molecule Inhibitors of Dusp6 and Uses Thereof” (owned by University of Pittsburgh)
• U.S. Patent No. 9,127,016
• U.S. Patent Application No. 14/795,056

For more information, please contact CTC Business Development at partnering@cchmc.org or 513-636-4285.

Previously Featured Technologies

Learn more about our previously featured technologies.